Group 1 - The core viewpoint of the news is that Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd. has shown a slight increase in revenue but a decrease in net profit in its latest quarterly report [1] - As of August 1, 2025, the company's stock price closed at 14.31 yuan, down 2.32%, with a trading volume of 239,600 hands and a transaction amount of 353 million yuan [1] - The company's main funds experienced a net outflow of 13.46 million yuan, accounting for 3.82% of the transaction amount, with significant outflows from large orders [1] Group 2 - For the first quarter of 2025, the company reported total operating revenue of 248 million yuan, a year-on-year increase of 4.28%, while the net profit attributable to shareholders decreased by 5.30% to 47.18 million yuan [1] - The company has a current ratio of 4.936, a quick ratio of 4.556, and a debt-to-asset ratio of 35.72% [1] - Anhui Shanhe Pharmaceutical Auxiliary Co., Ltd. was established in 2001 and is primarily engaged in the pharmaceutical manufacturing industry, with a registered capital of approximately 2.34 billion yuan [1][2]

Key Points - The article highlights significant announcements from various companies, including investment projects, performance data, and share buybacks [1][2] Company Announcements - Anzheng Fashion's controlling company, Lishang Information, has not engaged in the production of maternal and infant products [1] - New Aluminum Era plans to invest in a project to produce 800,000 sets of lightweight, high-strength auto parts annually [1] - Wanlima is expected to win a procurement project from China Southern Airlines [1] - Guangzhou Port anticipates a cargo throughput of 50.233 million tons in July, reflecting a year-on-year increase of 3.1% [1] - Shenma Co. intends to acquire a 10.27% minority stake in Nylon Chemical [1] - Fuanna plans to repurchase shares worth between 55.85 million to 104 million yuan [1] - Zhengdan Co. reported a 120.35% year-on-year increase in net profit for the first half of the year and plans to distribute 3 yuan per 10 shares [1] - Jieya Co. and Heyuan Gas's major shareholders plan to reduce their stakes by up to 4.95% and 2%, respectively [1][2] - Changhua Chemical aims to raise no more than 230 million yuan through a simplified procedure for a carbon dioxide polyether project [1] - Aoshikang plans to issue convertible bonds to raise no more than 1 billion yuan for a high-end printed circuit board project [1] Performance Data - Zhengdan Co. expects a significant increase in net profit for the first half of the year, with a proposed dividend distribution [2] - Jiejia Weichuang anticipates a net profit increase of 38.65% to 59.85% for the half-year [2] - Sinopec forecasts a 39.5% to 43.7% decline in net profit for the first half of the year [2]

证券代码：300452 证券简称：山河药辅 公告编号：2025-037 债券代码：123199 债券简称：山河转债 安徽山河药用辅料股份有限公司 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏。 安徽山河药用辅料股份有限公司（以下简称"公司"）第六届董事会 第六次会议于 2025 年 7 月 31 日上午在公司三楼会议室召开，应出席会议 董事 7 人，实际出席会议董事 7 人。公司第六届董事会第六次会议通知已 于 2025 年 7 月 28 日以电子邮件、 传真及电话通知的方式向全体董事送达， 会议由董事长尹正龙先生主持。会议的召开符合《中华人民共和国公司法》 和《公司章程》的有关规定。本次会议经审议逐项表决作出如下决议： 一、审议通过《关于续聘 2025 年度审计机构的议案》 经审议，董事会同意续聘容诚会计师事务所（特殊普通合伙）为公司 东会审议。关于 2025 年年度审计费用，公司董事会拟提请股东会授权管 理层根据公司的业务规模、所处行业以及事务所的收费标准等因素综合考 虑与审计机构协商确定。 表决结果：同意 7 票，反对 0 票，弃权 0 票。 此议案尚需提交公司 20 ...

（文章来源：证券日报） 证券日报网讯 7月31日晚间，山河药辅发布公告称，公司第六届监事会第六次会议审议通过了《关于续 聘2025年度审计机构的议案》等。 ...

（文章来源：证券日报） 证券日报网讯 7月31日晚间，山河药辅发布公告称，公司第六届董事会第六次会议审议通过了《关于续 聘2025年度审计机构的议案》等多项议案。 ...

证券日报网讯7月31日晚间，山河药辅（300452）发布公告称，公司将于2025年8月18日召开2025年第一 次临时股东会。本次股东会将审议《关于续聘2025年度审计机构的议案》等。 ...

（编辑 楚丽君） 证券日报网讯 7月31日晚间，山河药辅发布公告称，公司于2025年7月31日分别召开第六届董事会第六 次会议、第六届监事会第六次会议，审议通过了《关于拟续聘会计师事务所的议案》，同意续聘容诚会 计师事务所（特殊普通合伙）为公司2025年度年报及内部控制审计机构，聘期一年，并同意将该议案提 交公司2025年第一次临时股东会审议。 ...

格隆汇7月31日丨山河药辅(300452.SZ)公布，公司与淮南经济技术开发区管理委员会（简称"淮南经开 区管委会"）经友好协商，双方就公司在淮南经开化工园区投资建设高端辅料智造基地的相关事项达成 合作共识，拟签署高端辅料智造基地项目投资协议书。项目用地约200亩，总投资10.5亿元人民币，其 中固定资产投资6亿元人民币。项目分两期建设，其中本期项目用地约100亩，总投资4.5亿元人民币， 固定资产投资3亿元人民币，后期预留项目用地约100亩，总投资6亿元人民币，固定资产投资3亿元人民 币。项目内容：高端辅料智能生产线及质检、环保辅助设施等。 ...

格隆汇7月31日丨山河药辅(300452.SZ)公布，公司与淮南经济技术开发区管理委员会（简称"淮南经开 区管委会"）经友好协商，双方就公司在淮南经开化工园区投资建设高端辅料智造基地的相关事项达成 合作共识，拟签署高端辅料智造基地项目投资协议书。项目用地约200亩，总投资10.5亿元人民币，其 中固定资产投资6亿元人民币。项目分两期建设，其中本期项目用地约100亩，总投资4.5亿元人民币， 固定资产投资3亿元人民币，后期预留项目用地约100亩，总投资6亿元人民币，固定资产投资3亿元人民 币。项目内容：高端辅料智能生产线及质检、环保辅助设施等。 ...

Group 1 - The company, Shanhe Pharmaceutical Auxiliary, announced a collaboration with the Huainan Economic and Technological Development Zone Management Committee to invest in a high-end auxiliary material manufacturing base in the Huainan Chemical Park [2] - The project involves re-planning the remaining land from the company's new pharmaceutical auxiliary material production base project, which was previously announced [2] - The acquisition of land use rights is subject to uncertainty regarding the bidding, auction, or listing process, as well as the final transaction price and timing [2] Group 2 - For the year 2024, the company's revenue composition is entirely from the pharmaceutical manufacturing industry, with a 100% share [3]